Asymptomatic Patient with a Disc Hemorrhage, Thin Corneas, and Sleep Apnea
A 58-year-old software engineer presents for a routine examination. He has no ocular complaints. History includes obstructive sleep apnea (CPAP nightly), well-controlled hypertension, and a mother who lost vision from glaucoma in her 70s. Refraction is −1.25 DS OU with 20/20 acuity. IOP by Goldmann is 23 mmHg OD and 25 mmHg OS at 9:10 a.m.; pachymetry is 498 µm OD and 502 µm OS. Optic discs show vertical cup-to-disc ratios of 0.65 OD and 0.75 OS, with a splinter hemorrhage at the left inferotemporal rim and mild rim thinning. Gonioscopy is open to the ciliary body band in both eyes. Visual fields (24-2 SITA-Faster) are reliable and normal, with GHT within normal limits. The patient says he 'feels fine' and asks whether drops are really necessary, noting his father stopped his own glaucoma drops because of red eyes and fatigue.
1. Is this ocular hypertension, a glaucoma suspect, or glaucoma? Justify your classification and state whether you treat now.
Read the worked answer
Reframe the question: this is not 'ocular hypertension.' Three features move him past a simple IOP-based decision:
- A disc hemorrhage at the left inferotemporal rim is the most specific structural sign of glaucomatous damage; it converts a 'suspect' into probable early glaucoma, even with a normal field.
- CCT of ~500 µm means Goldmann readings underestimate true IOP by roughly 1.5–2 mmHg, so his functional IOP sits in the high 20s.
- CDR 0.65/0.75 with rim thinning, plus age, family history, and obstructive sleep apnea, load the risk model (OHTS risk factors: age, CCT, IOP, CDR, PSD).
A normal 24-2 field does not exclude pre-perimetric disease - roughly a third of ganglion cells can be lost before a reproducible defect appears, and a single field can be a false negative.
Decision: treat. Obtain baseline OCT RNFL/GCC and optic nerve photographs, repeat the field to establish variability, and consider a diurnal IOP curve. Treating a documented hemorrhage with a normal field is defensible; observing a hemorrhage is not. Document explicitly that the decision is risk-based, not field-based.
2. Set a target IOP and choose a first-line agent. Which drug would you avoid in this patient and why?
Read the worked answer
Target: a 25–30% reduction from the untreated baseline (~25 mmHg OS), i.e., mid-teens (15–17 mmHg), with the lower end for the eye with the hemorrhage. Write the numeric target in the record before starting therapy.
First-line: latanoprost 0.005%, one drop OU at bedtime. It gives the largest mean IOP reduction among monotherapy classes (25–33%), once-daily dosing suits a skeptical patient, and it carries no pulmonary or cardiac contraindication.
Avoid topical timolol. Systemically absorbed beta-blockade is associated with nocturnal bradycardia and worsening of apnea in patients with obstructive sleep apnea; he already uses CPAP and has hypertension. Avoid brimonidine as a first choice - fatigue and follicular conjunctivitis would feed directly into his 'my father's drops made him miserable' narrative.
Counsel on prostaglandin effects now, not later: early conjunctival hyperemia that usually fades, permanent iris darkening (irrelevant at his iris color), eyelash growth, and periorbital fat atrophy producing a deep lid sulcus after 1–2 years. Teach punctal occlusion to limit systemic exposure.
Offer SLT as an alternative. Comparable IOP lowering, no daily adherence requirement, no periorbitopathy - a good fit for a patient with apnea and drop skepticism.
3. Outline your follow-up and monitoring schedule and the triggers that would make you escalate or refer.
Read the worked answer
4–6 weeks after starting: IOP at the same time of day, adherence and instillation technique, hyperemia, and side effects. If not at target, consider SLT or a second agent (latanoprost plus dorzolamide or brimonidine; a latanoprost/timolol fixed combination is less attractive given the apnea).
At 3 months: repeat OCT and field. If stable, structural and functional testing every 6–12 months and IOP every 3–6 months. Because the baseline field was normal, progression will be judged primarily on OCT trend and disc photographs - get a second baseline field to define variability.
Escalation triggers: IOP above target on two consecutive visits, a new hemorrhage, OCT thinning exceeding test–retest variability, or a reproducible field defect.
Refer to glaucoma subspecialty if IOP cannot be controlled on two agents, if progression is rapid, or if the patient wishes to discuss surgical/laser options in depth.
Document the target, the rationale for treating a normal field, and the specific education provided. Send a copy of the plan to his primary care physician - OSA and blood pressure management both influence glaucoma risk and comorbidity.